Avectas’s technology allows cells to be taken from people, often critically ill, and returned to them after they have been genetically engineered to address their illness.

Serial entrepreneur Séamus Mulligan has led a $20 million (€18.3 million) fundraising in an Irish company that hopes to revolutionise the treatment of(...)